Therefore, based on the pathways and mechanistic study findings in murine gliomas, it is of clinical importance to detect prognostic signatures based on DEGs and associated pathways that underlie the effect of CSF-1R inhibition among RT-treated LGG patients to optimize novel therapeutic strategies. This evidence concerns the gene CSF1R and glioma.